强生公司（Johnson & Johnson）今日宣布，欧盟委员会已批准Lazcluze（lazertinib）与Rybrevant（amivantamab）联用，一线治疗携带表皮生长因子受体（EGFR ...

智通财经APP获悉，强生公司今日宣布，欧盟委员会已批准Lazcluze与Rybrevant联用，一线治疗携带表皮生长因子受体第19号外显子缺失或第21号外显子L858R ...

强生公司(JNJ.US)（Johnson & Johnson）今日宣布，欧盟委员会已批准Lazcluze（lazertinib）与Rybrevant（amivantamab）联用，一线治疗携带表皮生长因子受体（EGFR ...

Johnson & Johnson's recently approved combination of Rybrevant and Lazcluze has improved overall survival compared to AstraZeneca's Tagrisso in a head-to-head trial, claiming what could be a key ...

AstraZeneca's EGFR inhibitor Tagrisso has become the go-to therapy for EGFR-mutated non-small cell lung cancer (NSCLC), but now has competition from Johnson & Johnson's Rybrevant and Lazcluze ...

欧盟委员会的批准基于3期临床试验MARIPOSA的结果。该研究评估了Lazcluze联合Rybrevant，与活性对照osimertinib相比，一线治疗携带上述EGFR变异的NSCLC患者的 ...

Johnson & Johnson’s (J&J) combination therapy of Lazcluze (lazertinib) and Rybrevant (amivantamab-vmjw) has been granted marketing authorisation by the European Commission (EC) as a first-line ...

Lazcluze, also known as lazertinib, was co-developed by J&J and YuHan. The FDA approved the combination of Lazcluze and ...

Improvement in median OS is expected to exceed one year. The safety profile of rybrevant plus lazcluze was generally consistent with the profiles of the individual treatments. Adverse event rates ...

Johnson & Johnson’s (J&J) combination therapy of Lazcluze (lazertinib) and Rybrevant (amivantamab-vmjw) has been granted marketing authorisation by the European Commission (EC) as a first-line ...

Johnson & Johnson JNJ announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) rendered a positive opinion for the expanded use of the ...